long intergenic non-protein coding RNA 1725Genealiases: []
Q-omics provides the consensus-scored LINC01725 profile across patient tissues and cancer cell-line models. LINC01725 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC01725 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, LINC01725 RNA expression shows 15,556 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, THCA, and TGCT as cancer lineages where LINC01725 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01725 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01725 survival associations across molecular data types. LINC01725 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01725 RNA expression–survival associations across cancer types. High LINC01725 expression shows unfavorable associations in KIRP and KICH, but favorable associations in UVM, KIRC, ACC and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC01725 RNA expression.
This table summarizes LINC01725 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01725. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01725 shows lower tumor expression in THCA, KICH, KIRC, CHOL, KIRP and STAD. The THCA box plot shows higher LINC01725 RNA expression in normal versus tumor tissue (log2 FC = −0.609, t-test p < 0.001).
This table shows molecular features associated with LINC01725 in patient tissues and cancer cell lines. In patient samples, LINC01725 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
